ACCESS Newswire·Nov 2, 2026, 9:00 AM ET

CSO of Napo Pharmaceuticals, a Jaguar Health Family Company, and Clinical Investigators Evaluating Crofelemer Conduct Panel Discussion at Pediatric Gastroenterology Conference in Dubai (UAE)

Jaguar Health's subsidiary Napo Pharmaceuticals recapitulated a panel discussion on October 30, 2026, at the 2nd Best of Elite Ped-GI meeting in Dubai regarding intestinal failure & parenteral nutrition.
Panelists included Dr. Mohamad Miqdady, Dr. Christos Tzivinikos, & Pravin Chaturvedi, who discussed clinical challenges of microvillus inclusion disease (MVID) & short bowel syndrome (SBS-IF).
The panel reviewed data showing that over one year of liquid oral crofelemer treatment reduced parenteral support needs & improved growth parameters in pediatric MVID & SBS-IF patients.
Patients with intestinal failure require lifelong total parenteral nutrition (TPN) which carries serious risks, driving the need for alternative therapies like crofelemer.
Napo remains focused on its global development program for crofelemer powder for oral solution as an adjunctive therapy to parenteral support for rare intestinal failure diseases.
Data presented in June 2026 at the ESPGHAN meeting confirmed substantial reductions in weekly parenteral support requirements normalized to body weight with no significant clinical or laboratory abnormalities.
An ongoing randomized double-blind placebo-controlled crossover study in MVID patients is being conducted to meet regulatory requirements.
The company targets a New Drug Application (NDA) filing for MVID in mid-2027 based on expected clinical milestones from the pediatric program.